

Correction: Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56^{bright}CD16⁻ subset

Veneziani I, Alicata C, Pelosi A, *et al.* Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56^{bright}CD16⁻ subset. *J Immunother Cancer* 2022;10:e003385. doi:10.1136/jitc-2021-003385

This article has been corrected since it was first published. An error with figure 2 and the supplemental material has been amended.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2022;10:e003385corr1. doi:10.1136/jitc-2021-003385corr1

